Chlorothiazide

Overview

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

Indication

Chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Associated Conditions

Edema
Hypertension

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance	2018/07/02	NCT03574857	Phase 4	Terminated	University of Virginia
Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure	2015/11/17	NCT02606253	Phase 4	Completed	Vanderbilt University
Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure	2015/09/11	NCT02546583	Phase 1	Completed	Yale University
Treatment of Hypertension	1999/10/28	NCT00000484	Phase 3	Completed	National Heart, Lung, and Blood Institute (NHLBI)
Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus	1999/10/19	NCT00004360	N/A	Completed	National Center for Research Resources (NCRR)

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Chlorothiazide Sodium	Akorn	17478-419	INTRAVENOUS	500 mg in 1 1	8/10/2012
CHLOROTHIAZIDE SODIUM	Sun Pharmaceutical Industries, Inc.	47335-330	INTRAVENOUS	500 mg in 18 mL	10/1/2019
chlorothiazide sodium	Sagent Pharmaceuticals	25021-305	INTRAVENOUS	500 mg in 18 mL	10/23/2019
Sodium Diuril	Akorn	76478-711	INTRAVENOUS	0.5 mg in 18 mL	6/12/2012
Chlorothiazide	Fresenius Kabi USA, LLC	63323-658	INTRAVENOUS	500 mg in 18 mL	7/10/2017
Chlorothiazide	Fresenius Kabi USA, LLC	63323-658	INTRAVENOUS	500 mg in 18 mL	5/31/2023
Chlorothiazide	Fresenius Kabi USA, LLC	63323-658	INTRAVENOUS	500 mg in 18 mL	6/2/2023
chlorothiazide sodium	Sagent Pharmaceuticals	25021-305	INTRAVENOUS	500 mg in 18 mL	11/16/2020
Chlorothiazide Sodium	American Regent, Inc.	0517-1820	INTRAVENOUS	500 mg in 18 mL	6/5/2020
DIURIL	Salix Pharmaceuticals, Inc	65649-311	ORAL	250 mg in 5 mL	11/1/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access